Abstract
Bourgier et al . (1,2) performed a thoughtful randomized clinical trial in the hopes that it would shed light on a clinically relevant topic, that lacks good evidence—what is the ideal sequence of endocrine therapy (ET) and radiation (RT) in women who receive breast conserving therapy for early stage hormone-receptor positive breast cancer? Moreover, the investigators also sought to identify a biomarker for radiation-induced subcutaneous fibrosis (RISF), using cutting edge for a translational science.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
